Cyclenium Pharma and Vuja De Sciences collaborate on oncology drug discovery
pharmafile | January 6, 2022 | News story | Business Services |
Cyclenium Pharma, an emerging pharmaceutical company, have announced a collaboration with Vuja De Sciences, to screen and optimise lead candidates to advance treatments uniquely suited for preventing cancer metastatic recurrence.
Vuja De is a biotechnology startup, dedicated to discovering therapies that target the unique vulnerability of undetected disseminated tumour cells before they can cause deadly metastatic cancer recurrence. Cyclenium Pharma specialises in the discovery and development of novel therapeutic agents based on their proprietary macrocyclic chemistry.
The collaboration will make use of Vuja De’s proprietary anti-metastatic progression in vitro and ex vivo drug discovery screening platform, and Cyclenium’s proprietary QUEST Library of next generation synthetic small-molecule macrocycles. This will allow the companies to identify clinical candidates effective against dormant disseminated tumour cells, for the prevention of metastatic cancer recurrence.
“We are very excited about entering this collaboration with Vuja De,” stated Helmut Thomas, PhD, President, CEO & Chief Scientific Officer of Cyclenium. “We are confident that our CMRT™ Technology and proven success in the macrocycle area combined with the innovative anti-metastatic progression platform and excellent research team at Vuja De will enable the discovery and development of novel macrocyclic therapeutic agents to effectively control metastatic progression.”
“We highly appreciate Cyclenium’s expertise in the macrocycle area and their technology platform that is based on over 20 years of pioneering experience in small molecule macrocyclic chemistry,” said David Warshawsky, PhD, CEO of Vuja De.
“We are very pleased to work with Cyclenium on identifying and developing novel game-changing drug candidates that prevent metastatic recurrence, the most urgent need of most cancer patients,” he added.
Lina Adams
